Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,066 shares of the medical research company's stock after selling 1,205 shares during the quarter. Thermo Fisher Scientific makes up 2.8% of Arcadia Investment Management Corp MI's portfolio, making the stock its 11th biggest holding. Arcadia Investment Management Corp MI's holdings in Thermo Fisher Scientific were worth $15,458,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $25,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $30,000. Cassady Schiller Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 89.2% during the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after purchasing an additional 33 shares during the period. VSM Wealth Advisory LLC bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $36,000. Finally, Navigoe LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth about $37,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Up 1.0%

NYSE TMO traded up $4.29 on Friday, reaching $435.02. The stock had a trading volume of 2,511,384 shares, compared to its average volume of 1,995,412. The firm has a market capitalization of $164.22 billion, a price-to-earnings ratio of 25.51, a P/E/G ratio of 2.29 and a beta of 0.77. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average price of $409.39 and a two-hundred day moving average price of $476.59. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the business earned $5.11 EPS. Thermo Fisher Scientific's revenue was up .2% on a year-over-year basis. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Evercore ISI cut their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday. Barclays dropped their target price on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a report on Tuesday, June 24th. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Finally, Argus lowered their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $600.30.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.